← All trials
NCT03123770
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 384
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityCollaborator
- First People's Hospital of HangzhouCollaborator
- Jinhua Central HospitalCollaborator
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversityStudy chair
- Hangzhou Hospital of Traditional Chinese MedicineCollaborator
- Ningbo No. 1 HospitalCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.